Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229192 | PMC |
| http://dx.doi.org/10.1161/JAHA.124.038991 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Polyomavirus Antibodies for Merkel Cell Carcinoma Recurrence Detection.
JAMA Dermatol
September 2025
Department of Dermatology, University of Washington, Seattle.
Importance: Merkel cell carcinoma (MCC) is typically caused by the Merkel cell polyomavirus (MCPyV) and recurs in 40% of patients. Half of patients with MCC produce antibodies to MCPyV oncoproteins, the titers of which rise with disease recurrence and fall after successful treatment.
Objective: To assess the utility of MCPyV oncoprotein antibodies for early detection of first recurrence of MCC in a real-world clinical setting.
Antiplatelet therapy and central nervous system hematomas: a cohort study using real-world data from the FAERS and vigiaccess databases.
Int J Surg
September 2025
Department of Pharmacy, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, School of Clinical Medicine, Henan University, Zhengzhou, Henan, China.
Background: Antiplatelet therapy is a cornerstone in the management of atherosclerotic cardiovascular disease. However, the risk profile of central nervous system (CNS) hematomas associated with antiplatelet agents remains incompletely characterized.
Methods: We analyzed CNS-related hematoma adverse event (hAE) reports across the four antiplatelet drugs, using data from the U.
From Trials to Practice: A 2025 Review of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel Efficacy Across Clinical Studies and Real-World Evidence.
Eur J Haematol
September 2025
Department of Hematology-Oncology, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies have revolutionized the approach and management of relapsed/refractory multiple myeloma (RRMM), and as of 2025, idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are the only BCMA-targeted CAR T-cell therapies approved by the FDA. Exceptional responses were demonstrated for heavily pretreated patients in the KarMMa-1 trial, reporting a 73% overall response rate (ORR) and 98% in the CARTITUDE-1 trial. Furthermore, both therapies show a significant improvement in progression-free survival (PFS) compared to standard regimens when administered in earlier lines.
View Article and Find Full Text PDFIndication for biologics in a real-world cohort of dupilumab treated chronic rhinosinusitis with nasal polyps patients according to international recommendations: evidence from the European CRS Outcome Registry (CHRINOSOR).
Rhinology
September 2025
Allergy and Clinical Immunology Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Belgium.
Background: Criteria for biologic treatment of uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) differ across international recommendations and prescription of biologics depends on national reimbursement criteria. CHRINOSOR offers an opportunity to analyse biologic indications in the real-world setting according to international recommendations.
Methods: CRSwNP patients who received dupilumab treatment in the ENT clinic of 6 tertiary centres (5 countries) were included.
The Role of Vericiguat in Heart Failure Therapy: From Clinical Trials to Clinical Practice.
Rev Cardiovasc Med
August 2025
Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.
Heart failure with reduced ejection fraction (HFrEF) is a progressive condition that is associated with high rates of morbidity, frequent hospitalizations, and significant mortality. Despite advancements in guideline-directed medical therapy (GDMT), many patients continue to be at risk for worsening heart failure (WHF). Vericiguat is a novel soluble guanylate cyclase (sGC) stimulator that targets the impaired nitric oxide (NO)-sGC-cyclic guanosine monophosphate (cGMP) pathway.
View Article and Find Full Text PDF